WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
1. (WO2001027137) RATTUS NORVEGICUS (EDG3)
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/027137    International Application No.:    PCT/US2000/028231
Publication Date: 19.04.2001 International Filing Date: 12.10.2000
Chapter 2 Demand Filed:    08.05.2001    
C07K 14/705 (2006.01)
Applicants: SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza Philadelphia, PA 19130 (US).
SMITHKLINE BEECHAM PLC. [GB/GB]; Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB)
Inventors: LANE, Pamela; (US).
TSUI, Ping; (US).
Agent: ANDERSEN, Robert, L.; Ratner & Prestia, 301 One Westlakes (Berwyn), P.O. Box 980, Valley Forge, PA 19482-0980 (US).
PRESTIA, Paul, F.; Ratner & Prestia, 301 One Westlakes, Berwyn, P.O. Box 980, Valley Forge, PA 19482-0980 (US)
Priority Data:
60/159,019 12.10.1999 US
09/686,105 11.10.2000 US
Abstract: front page image
(EN)Rattus norvegicus EDG3 polypeptides and polynucleotides and method for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds which either agonize or antagonize Rattus norvegicus EDG3. Such compounds are expected to be useful in treatment of human diseases, including, but not limited to: infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; stroke; ulcers, asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, dementia, and severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles de la Tourett's syndrome.
(FR)Cette invention concerne des polypeptides et des polynucléotides Rattus norvegicus EDG3 ainsi qu'un procédé permettant de produire lesdits polypeptides au moyen de techniques recombinantes. L'invention porte également sur des techniques de criblage de composés qui sont soit des agonistes, soit des antagonistes de Rattus norvegicus EDG3. Ces composés devraient s'avérer utiles dans le traitement des pathologies humaines dont la liste suivante n'est pas limitative : infections, notamment bactériennes, fongiques, par des protozoaires et virales, en particulier infections par VIH-1 ou VIH-2; douleurs; cancers;diabète, obésité; anorexie; boulimie; asthme; maladie de Parkinson; défaillances cardiaques aiguës; hypotension; hypertension; rétention urinaire; ostéoporose; angine de poitrine; infarctus du myocarde; attaque; ulcères, asthme; allergies; hypertrophie de la prostate; migraine; vomissements; troubles psychotiques et neurologiques, dont manifestations d'angoisse, schizophrénie, psychose maniaco-dépressive, dépression, démence, et arriération mentale grave; et dyskinésie, telle que maladie de Huntington ou syndrome de Gilles de la Tourette.
Designated States: JP.
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)